Claims
- 1. A method of providing cardioprotection, or protecting against reperfusion injury, or protecting against ischemic injury, in a patient in need thereof comprising administering to said patient a pharmaceutically effective amount of a compound having adenosine A1/A2 agonistic activity, beginning at a time less than ten minutes after the onset reperfusion, and continuing for a period of more than 30 minutes following the onset of reperfusion.
- 2. A method according to claim 1, wherein the cardioprotection is provided prior to, during, or following cardiac surgery.
- 3. A method according to claim 1, wherein the cardioprotection is provided prior to, during, or following ischemic attack.
- 4. A method according to claim 1 wherein the administering of the compound begins at the onset of reperfusion, and continues for a period of more than 30 minutes following the onset of reperfusion.
- 5. A method according to claim 1, wherein the administering of the compound is continued for a period of more than 70 minutes after the onset of reperfusion.
- 6. A method according to claim 1, wherein the compound is of the formula
- 7. A method according to claim 1, wherein the compound is administered as a pharmaceutically acceptable salt thereof.
- 8. A method according to claim 1, wherein the compound administered is contained in a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of the compound.
- 9. A method of providing cardioprotection, or protecting against reperfusion injury, or protecting against ischemic injury, in a patient in need thereof comprising administering to said patient a pharmaceutically effective amount of a compound having adenosine A1/A2 agonistic activity, beginning at a time 10 minutes or more before the onset of reperfusion, and continuing for a period of more than 30 minutes after the onset of reperfusion.
- 10. A method according to claim 9, wherein the cardioprotection is provided prior to, during, or following cardiac surgery.
- 11. A method according to claim 9, wherein the cardioprotection is provided prior to, during, or following ischemic attack.
- 12. A method according to claim 9, wherein the administering of the compound is continued for a period of more than 70 minutes after the onset of reperfusion.
- 13. A method according to claim 9, wherein the compound is of the formula
- 14. A method according to claim 9, wherein the compound is administered as a pharmaceutically acceptable salt thereof.
- 15. A method according to claim 9, wherein the compound administered is contained in a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of the compound.
Priority Claims (1)
Number |
Date |
Country |
Kind |
0120124.3 |
Aug 2001 |
GB |
|
Parent Case Info
[0001] This application is a continuation of International Application No. PCT/US02/14228, filed May 3, 2002, which claims the benefit of Provisional Application No. 60/288,936, file May 4, 2001.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60288936 |
May 2001 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/US02/14228 |
May 2002 |
US |
Child |
10696527 |
Oct 2003 |
US |